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AbstrAct
chronic kidney disease (cKD) represents a challenge in the treatment of type 2 diabetic 
patients. renal impairment may affect drug clearance and other pharmacokinetic processes 
which can increase toxicity and drug to drug interactions or cause ineffective therapy. there 
are many oral glucose lowering drugs available for the treatment of type 2 diabetes mellitus 
(t2DM) with different mechanisms of action and different pharmacokinetic profiles. While all 
classes may be used in patients with mild renal impairment, therapeutic options for patients 
with moderate to severe cKD are still limited. this review focuses on the pharmacokinetics, 
metabolism, and safety of oral glucose lowering drugs in patients with t2DM and cKD.
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clearance, and peripheral tissue sensitivity to insulin.3 
Several factors contribute to hyperglycemia, namely 
decreased insulin production and insulin resistance.
Accumulation of uremic toxins (which blunt abil-
ity to suppress hepatic gluconeogenesis), chronic 
inflammation, excess visceral fat, oxidative stress, and 
metabolic acidosis can all affect the insulin signaling 
pathway and induce insulin resistance. On the other 
hand, hypoglycemia may also develop in patients 
with advanced CKD due to accumulation of uremic 
toxins, which lead to lower hepatic and renal insulin 
degradation, and also as a result of decreased renal 
gluconeogenesis, uremic malnutrition, and deficient 
catecholamine release. Assessment of glucose con-
trol in patients with progressive kidney disease by 
measuring HbA1c may also be a challenge. Falsely 
increased values may occur as a result of carbamyla-
IntroductIon
Type 2 diabetes mellitus (T2DM) is one of the 
most common metabolic disorders worldwide with its 
prevalence being unprecedented in both developed 
and developing countries.1 T2DM is the leading cause 
of end-stage renal disease (ESRD) all over the world, 
while patients with CKD of other etiologies may also 
develop T2DM.2 Management of T2DM in patients 
with renal impairment is a complex process that re-
quires a comprehensive approach. Clinicians must be 
aware that as renal function worsens, abnormalities 
in glucose homeostasis develop, affecting secretion, 
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tion of the hemoglobin and acidosis. Meanwhile, 
reduced red blood cell lifespan, transfusions, and 
hemolysis may contribute to falsely reduced HbA1c 
values. Nevertheless, HbA1c remains the best clinical 
marker of long-term glycemic control, particularly 
if combined with self-monitoring of blood glucose.4 
Glycated albumin, as an alternative, reflects glycemic 
control over a 2-week period and may be of greater 
value for predicting clinical outcomes in patients 
with advanced CKD. Besides considering the par-
ticularities of treating T2DM in patients with CKD, 
clinicians should also be aware of the therapeutic 
options. Many drugs are available for treatment of 
T2DM, namely biguanides, sulfonylureas (SUs), 
meglitinide analogues, thiazolidinediones (TZDs), 
alpha-glucosidase inhibitors, dipeptidylpeptidase-4 
(DPP-4) inhibitors, dopamine receptor agonists, and 
in the near future sodium-glucose co-transporter 
(SGLTs) inhibitors and G-protein coupled receptor 
40 agonists (GPR 40). Although all drugs can be used 
in patients with mild renal impairment,4,5 therapeutic 
options for patients with moderate to severe CKD 
or with ESRD are limited, since drug or metabolite 
accumulation may occur due to a reduced glomerular 
filtration rate (GFR) resulting in increasing side ef-
fects. In this case, some drugs are not recommended, 
while others can be used with dose adjustment. This 
paper reviews the pharmacokinetics, metabolism, 
and safety of oral glucose lowering drugs in patients 
with T2DM and CKD.
orAL HYPoGLYcEMIc druGS
Biguanides
Metformin, the only available biguanide, is the first 
line drug in T2DM therapy.5 It acts mainly by decreas-
ing hepatic glucose production, but also increases 
peripheral glucose uptake and reduces intestinal 
glucose production, improving glucose tolerance and 
lowering fasting and postprandial plasma glucose.6 It 
is predominantly absorbed in the small intestine and 
its peak plasma concentrations are attained 3 hours 
after intake. Metformin does not bind to plasma 
proteins and it is excreted unchanged in urine. The 
elimination half-life (t½) is approximately 5 hours. 
Metformin does not cause hypoglycemia nor 
weight gain5 and has been shown to reduce long-
term diabetes complications, although the effect on 
macrovascular disease is controversial.7 In a meta-
analysis of 35 randomized clinical trials, including 
7,171 and 11,301 participants treated with metformin 
and comparator, respectively, metformin was asso-
ciated with a reduction of cardiovascular risk when 
compared with placebo or no therapy, whereas its 
effect disappeared when active-comparator trials 
were included.8 The authors speculated that the 
cardiovascular protection conferred is related to the 
improvement of glucose control. 
The most common adverse reactions to metformin 
are gastrointestinal but the most feared reaction, 
although rare, is lactic acidosis.5,9 A meta-analysis 
of 347 studies assessed the incidence of lactic acido-
sis in patients on metformin treatment for at least 
one month compared to placebo or non-metformin 
therapies.10 There were no cases of fatal or nonfatal 
lactic acidosis in 70,490 patient-years of metformin 
use or in 55,451 patients-years in the non-metformin 
group. The upper limit for the true incidence of lactic 
acidosis per 100,000 patient-years was 4.3 cases in the 
metformin group and 5.4 cases in the non-metformin 
group. In a subgroup of patients with mild to moderate 
CKD, there was no difference in the incidence of lactic 
acidosis. Furthermore, there is no correlation between 
levels of metformin and lactate in patients with lactic 
acidosis, and its prognosis is mainly related to the se-
verity of the underlying condition and comorbidities.9 
The risk of lactic acidosis is enhanced by conditions 
that cause hypoxia and which predispose patients to 
lactate production and accumulation such, as heart 
failure and pulmonary chronic disease, or diseases 
that reduce lactate clearance (e.g. liver dysfunction). 
The evidence suggests that metformin can be safely 
used in patients with creatinine <1.5mg/dL. Since 
serum creatinine may overestimate renal function, 
calculation of the estimated GFR (eGFR) is preferred. 
The clearance of metformin decreases by about 75% 
when the eGFR is <60mL/min/1.73m2 without ad-
ditional changes when the eGFR declines to 30mL/
min/1.73m2.11 At these levels of renal impairment, 
serum concentration of metformin is only about two-
fold higher than in normal kidney function. Current 
United Kingdom (UK) guidelines on the treatment 
of T2DM allow metformin use until an eGFR of 
30mL/min/1.73m2 with dose reduction advised at 
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45mL/min/1.73m2.9,12 In the USA, metformin is con-
traindicated for men with serum creatinine ≥1.5mg/
dL and for women with serum creatinine ≥1.4mg/
dL;5 eGFR calculated for these creatinine values 
ranges from 66mL/min/1.73m2 in a 20-year-old man 
(54mL/min/1.73m2 in a 20-year-old woman) to 43mL/
min/1.73m2 in an 80-year-old man (36mL/min/1.73m2 
in an 80-year-old woman). 
A recent observational study of 51,675 T2DM 
patients with a mean follow-up of 3.9 years supports 
the NICE guideline recommendations.13 A composite 
endpoint including acidosis, shock, acute renal failure 
and serious infections was used to evaluate the occur-
rence of lactic acidosis. Metformin, compared with 
any other treatment, showed reduced risks of acidosis/
serious infection and all-cause mortality in patients 
with eGFR 45-60mL/min/1.73m2, and no increased 
risks of all-cause mortality, acidosis/serious infection 
or cardiovascular disease were found in patients with 
eGFR 30-45mL/min/1.73m2. A prospective observa-
tional study evaluated acute kidney injury and lactic 
acidosis in patients treated with metformin.14 A total 
of 29 cases were identified over 4 years; however, 
moderate renal impairment was not associated with a 
higher risk of dialysis-dependent acute kidney injury 
in patients who develop lactic acidosis and it seems 
not to influence prognosis. In this study, an episode 
of acute gastroenteritis precipitated the event in 26 
cases, showing that volume depletion and hypoperfu-
sion appear to aggravate the severity of metformin-
related metabolic acidosis when associated with an 
acute kidney injury.
Although the use of metformin in moderate CKD 
is still controversial, we think that its use should be 
avoided in patients with CKD stages 3-5 with other 
risk factors for lactic acidosis. In patients without risk 
factors, the available evidence suggests that metformin 
may be safely used without dose adjustment in CKD 
stage 3A and with half-dose reduction in stage 3B 
(Table 1). Patients should be encouraged to inter-
table 1. Dosing adjustment for oral hypoglycemic drugs according to CKD stage
class Drug









biguanides Metformin No dose adjustment1 Half-dose1 Avoid
sulfonylureas Glibenclamide Avoid
Glipizide
No dose adjustment No dose adjustment2
Gliclazide





Initiate at low dose (60mg) Avoid
Repaglinide Initiate at low dose (0.5mg)















Linagliptin No dose adjustment
1Avoid if patient has other risk factors for lactic acidosis; these levels are controversial.
2Glipizide is the preferred sulfonylurea; however, safer options which carry no risk of hypoglycemia should be considered.
3Although it is not contraindicated in patients with advanced CKD, the possibility of fluid retention and bone disease may limit its use.
4Dose adjustment required for GFR <50mL/min.
Adapted from National Kidney Foundation, 2012 KDOQI Clinical Practice Guideline for Diabetes and CKD: 2012 Update. Am J 
Kidney Dis 60: 850-886.4
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rupt their metformin treatment in the case of acute 
volume depletion such as gastroenteritis. 
Sulfonylureas
Sulfonylureas bind to the SU receptor and close the 
KATP-dependent potassium channel in the pancreatic 
beta-cells, altering the resting potential of the cell.15 
This leads to calcium influx and stimulation of insulin 
secretion. SUs are well absorbed and peak concentra-
tions are reached within 1-4 hours. They are tightly 
bound to plasma albumin (90-99%) and have a small 
volume of distribution.16 Since SUs stimulate insulin 
secretion independent of blood glucose levels, they 
may cause hypoglycemia, especially the long-acting 
SUs.15 They may also reduce hepatic gluconeogenesis 
and glycogenolysis and increase glucose uptake in the 
liver and utilization in the skeletal muscles. 
Glibenclamide is a long-acting (24h) SU metabo-
lized in the liver, mainly to 2 metabolites (M1 and 
M2).17 In normally functioning humans, 30-60% of 
M1 and M2 are excreted in the urine and the rest by 
biliary secretion. M1 and M2 may have a hypoglycemic 
effect. In a study that evaluated the pharmacokinetics 
of a single dose (7mg) of glibenclamide in patients 
with CKD, very small amounts of M1 and M2 were 
excreted in urine in the renally impaired group and 
diabetic patients had slightly higher serum levels 
of metabolites than the normal function group.17 
Neither glibenclamide nor its metabolites seemed 
to accumulate in patients with severe CKD after a 
single dose of glibenclamide, which may indicate that 
complementary non-renal elimination routes might 
operate in these subjects. However, during chronic 
therapy one or more metabolites may accumulate in 
patients with CKD, resulting in an increased risk of 
hypoglycemia. 
Glipizide is rapidly absorbed, reaching peak con-
centrations after 1.5 hours.18 It undergoes hepatic 
metabolism in several inactive metabolites and elimi-
nation t½ is 2-3 hours. However, the duration effect 
of a single dose of 7.5mg glipizide lasts around 12-14 
hours. About 60% of glipizide is excreted as me-
tabolites and less than 10% unchanged in urine. One 
study in two patients with a GFR of 30ml/min and 
10 ml/min showed an increase of the t½ of glipizide 
metabolites to 20h and more.19 Although several 
metabolites accumulate in patients with CKD, they 
do not seem to cause an increased risk of hypoglyce-
mia.20 Of the second-generation SUs, glipizide is the 
preferred agent, since it does not increase the risk of 
hypoglycemia in patients with CKD.
Gliclazide is extensively metabolized into 7 inac-
tive metabolites and mainly excreted in the urine.21 
Renal insufficiency has little effect on the pharma-
cokinetic profile of gliclazide. Efficacy and safety 
of gliclazide modified release was evaluated in a 
double-blind trial over 2 years.22 Of the 507 T2DM 
patients who completed the study, 20% had mild to 
moderate CKD (CrCl 20-80mL/min) and no excess in 
frequency of hypoglycemia symptoms was observed 
in this subgroup. This was not related to a reduction 
in glycemic control, as final HbA1c was similar in 
the whole population. Gliclazide safety profile has 
been well established in clinical studies performed 
in patients with mild to moderate renal impairment.
Glimepiride is completely absorbed and under-
goes extensive hepatic metabolism to the active M1 
metabolite, with further dehydrogenation to the in-
active M2 metabolite.23 The elimination t½ is about 
5-8 hours. About 37-52% of a glimepiride dose is 
found in the urine as M1 or M2 within 48 hours, with 
the remainder appearing in feces. Although glime-
piride clearance tends to increase in patients with 
CKD as creatinine clearance decreases, the terminal 
t½ is unaffected. However, urinary clearance of its 
metabolites decreases with creatinine clearance.20 
Since prolonged hypoglycemia has been described 
in patients with CKD under glimepiride therapy, its 
use in this group of patients should be discouraged.
The recommendations for the use of SUs in pa-
tients with CKD are summarized in Table 1. Gliben-
clamide should be avoided in patients with moderate 
to severe CKD. Glipizide and gliclazide may be used 
in patients with CKD stages 3 to 5 without dose ad-
justment. Glimepiride may also be used in patients 
with CKD stages 3 and 4 with dose adjustment to a 
maximum of 1mg/day. However, caution must be 
taken in relation to the risk of hypoglycemia. Since 
T2DM patients with CKD often have other comor-
bidities and may be old and frail, safer alternatives 
are preferred. 
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Meglitinide analogues
Meglitinide analogues stimulate insulin release 
by inhibiting KATP-dependent channels of the β-cell 
membrane.24 They are rapidly absorbed, stimulat-
ing insulin release within a few minutes, and are 
metabolized in the liver and mainly excreted in bile. 
Following preprandial administration, insulin is more 
readily available during and just after the meal, which 
leads to a reduction in postprandial hyperglycemia 
without the danger of hypoglycemia between meals.
Nateglinide reaches its peak plasma concentration 
in less than an hour.25 It binds extensively (98%) to 
serum proteins and is predominantly metabolized 
by cytochrome P450 isoenzymes CYP2C9 (70%) 
and CYP3A4 (30%). Several metabolites have been 
identified in plasma and urine but only M1 has sig-
nificant pharmacological activity. Most nateglinide 
pharmacological activity is attributed to the parent 
compound.26 It is rapidly eliminated with a t½ of 2.91 ± 
1.84 hours. Between 20-30% of the dose is eliminated 
unchanged in the bile and urine. Approximately 2/3 
is excreted in the feces and 1/3 in urine. Nateglinide 
is well tolerated and has a low risk of hypoglycemia.27 
In patients with CKD, a single dose of 90mg was 
safe and effective.28 Compared to healthy subjects, 
patients with T2DM and moderate to severe CKD 
(CrCl 15-50mL/min) displayed similar clearance, 
AUC, and Cmax.29 Patients with T2DM on dialysis 
exhibited reduced overall drug exposure.30 A pooled 
analysis of elderly patients with renal impairment (n 
= 333) did not reveal an increased incidence of con-
firmed hypoglycemia in this population.31 However, 
an increase in the levels of the active metabolite M1 
occurs with decreased renal function, which may 
increase the risk of hypoglycemia. Evidence suggests 
that nateglinide may be safely used in patients with 
CKD stage 3, but in patients with a GFR <30 mL/
min/1.73m2 it should be initiated conservatively at 
60mg with meals.
Repaglinide is rapidly absorbed with maximum 
concentrations attained within an hour.32 There is a 
high (68.8%) inter-individual variation in the AUC 
after multiple doses in patients with T2DM that may 
be explained by differences in activity of CYP450 
enzymes that metabolize repaglinide. It is rapidly 
and completely metabolized to M1 and M2. No 
metabolites with clinically relevant hypoglycemic ef-
fects have been identified.32 Repaglinide is primarily 
eliminated by the liver and its metabolites are biliary-
fecal excreted. Within 96 hours, 90% of the drug is 
eliminated as metabolites via the feces and 8% in the 
urine. Repaglinide is generally well tolerated and hy-
poglycemic events are rare.33 In patients with mild to 
moderate CKD, there are no clinically relevant effects 
in relation to the pharmacokinetics of repaglinide. 
In patients with T2DM and severe CKD, exposure 
to repaglinide appears to be elevated. Therefore, 
repaglinide may be safely used in CKD stage 3, but 
when GFR is <30 mL/min/1.73m2 treatment should 
be started at a 0.5mg dose with each meal.34
Thiazolidinediones
Thiazolidinediones activate the nuclear peroxisome 
proliferator activated receptor-γ (PPAR-γ), which 
is thought to be involved in the modulation of the 
expression of genes coding for proteins involved in 
glucose and lipid metabolism.35 These proteins amplify 
the post-receptor actions of insulin in the liver and 
peripheral tissues, resulting in improved glycemic 
control with no increase in endogenous insulin secre-
tion.36 Since rosiglitazone was withdrawn from the 
European market in 2010 due to its potential risk of 
causing ischemic heart disease and is available in the 
US only with significant restrictions on prescription, 
we will focus our discussion on pioglitazone.
Pioglitazone is well absorbed after oral administra-
tion, with peak concentrations achieved approximately 
1.5 hours later.36 It is highly bound to plasma proteins 
and has a low tissue distribution and slow elimination 
(t½ about 9 hours). It undergoes extensive hepatic 
metabolism and its major active metabolites, M-III 
and M-IV, have considerably longer terminal t½ 
than the parent compound. It is excreted as inactive 
metabolites in the feces.
A study in 21 individuals with severe (CrCl <30mL/
min) or moderate (CrCl 30-60mL/min) CKD and 
6 healthy volunteers receiving single and multiple 
doses of pioglitazone 45mg revealed no significant 
accumulation of the drug and its metabolites.37 After 
single and repeated oral doses, mean AUC values were 
decreased in patients with severe CKD compared with 
healthy subjects for pioglitazone, M-III and M-IV 
metabolites. This may be explained by reduced protein 
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binding resulting in increased free pioglitazone. The 
tolerability and safety profile of pioglitazone was com-
parable between groups. In patients on hemodialysis, 
pioglitazone was effective and safe, with no increase 
in adverse effects.38,39 The most common adverse ef-
fects of pioglitazone are weight gain, fluid retention, 
a twofold increased risk of congestive heart failure, 
and an increase in fracture rates and bone loss.36 The 
mechanism through which thiazolidinediones induce 
fluid retention is controversial. Most studies suggest 
that this effect results from the increase in tubular 
sodium and water reabsorption in the kidney, but 
the role of specific nephron segments and sodium 
carriers involved is less clear.40 Some studies suggest 
that PPAR γ agonist stimulates Na(+) reabsorption 
in the collecting duct by activating the epithelial 
Na(+) channel (ENaC). Alternative mechanisms in 
the collecting duct include stimulation of non-ENaC 
sodium channel or inhibition of chloride secretion to 
the tubular lumen. In addition, thiazolidinediones 
may augment sodium reabsorption in the proximal 
tubule by stimulating the expression and activity 
of apical Na(+)/H(+) exchanger-3 and basolateral 
Na(+)-HCO3 (-) co-transporter, as well as that of 
Na(+)/K(+)-ATPase. These effects are mediated 
by PPAR γ -induced non-genomic transactivation 
of the epidermal growth factor receptor and down-
stream extracellular signal-regulated kinases (ERK).40 
Therefore, pioglitazone is not recommended in New 
York Heart Association (NYHA) Class III and IV 
heart failure.41 There is also some concern about a 
possible association with bladder cancer.42 Although 
no dose adjustment in patients with CKD stages 3 
to 5 is recommended,4 its use in patients with CKD 
should be balanced with the possibility of worsening 
of fluid retention and fractures, the latter particularly 
in patients with underlying bone disease (such as 
renal osteodystrophy).
Alpha-glucosidase inhibitors
The α-glucosidase inhibitors bind reversibly to the 
oligosaccharide binding site of α-glucosidases, which 
are enzymes located in the brush-border membrane 
of the small intestine responsible for the digestion of 
complex polysaccharides and sucrose.43 The inhibition 
of α-glucosidase delays the production of monosac-
charides, reducing postprandial hyperglycemia and 
hyperinsulinemia. The main side effects, flatulence, 
abdominal distension, and diarrhea, are more fre-
quently reported in the first 3 months of treatment 
and seem to be dose-dependent.44-46 
Acarbose is minimally absorbed in unchanged form 
and has extremely limited systemic availability.43 It is 
extensively metabolized by gastrointestinal amylases 
and intestinal flora, yielding at least 13 metabolites, 
one of which has one third of acarbose activity. In 
subjects with normal renal function, 35% is recovered 
in urine and about 50% in feces. The elimination t½ 
is about 2.8 hours, although a more slowly declining 
terminal phase exists with a t½ of approximately 9 
hours. Patients with CrCl <25mL/min/1.73m2 attained 
peak plasma concentrations of acarbose which were 
about 5 times higher than volunteers with normal 
renal function. Their AUCs were 6 times greater than 
the volunteers’.47 Acarbose is not recommended in 
patients with GFR <26mL/min/1.73m2.4 
Miglitol absorption is saturable at high doses and 
exhibits peak concentrations in 2-3 hours.48 It is sys-
temically absorbed rather than metabolized and it is 
eliminated by renal excretion as an unchanged drug. 
At doses higher than 25mg, the cumulative recovery 
of drug from urine is lower due to the incomplete bio-
availability. The elimination t½ of miglitol is approxi-
mately 2 hours. In patients with CKD, accumulation 
of miglitol is expected. Patients with CrCl <25 mL/
min taking 25mg 3 times daily exhibited a greater than 
two-fold increase in miglitol plasma levels compared 
to subjects with CrCl >60mL/min. Little information 
is available on the safety of miglitol in patients with 
CrCl <25mL/min. Miglitol is not recommended in 
patients with GFR <25mL/min/1.73m2.4 
Dipeptidyl peptidase-4 inhibitors
DPP-4 inhibitors improve glycemic control by 
preventing the inactivation of the incretin hormones 
glucagon-like peptide-1 and glucose-dependent in-
sulinotropic polypeptide.49 The increase of incretin 
hormones stimulates insulin secretion and reduces 
postprandial glucagon in a glucose-dependent fash-
ion. The first in class was sitagliptin approved in 
2006, followed by vildagliptin in 2007, saxagliptin 
in 2009, alogliptin in 2010, and linagliptin in 2011.50 
These drugs are not more efficient in lowering blood 
glucose concentrations and reducing HbA1c levels 
than the older molecules. Nevertheless, they offer 
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several clinical advantages.5 Among the most im-
portant are a negligible risk of hypoglycemia and 
a weight-neutral profile. These two side effects are 
clinically relevant since hypoglycemia is associated 
with increased mortality and, in patients losing weight, 
a 1% decrement in HbA1c was associated with an 
HR of 0.91 (0.83, 0.99) for the all-cause mortality 
endpoint.51 For participants not losing weight, each 
1% decrease in HbA1c was associated with an HR 
of 1.00 (0.88, 1,15).52
DPP-4 inhibitors are rapidly absorbed, with sig-
nificant inhibition of plasma DPP-4 activity achieved 
within 5 minutes of administration.50 All gliptins, ex-
cept linagliptin, are poorly bound to plasma proteins. 
Sitagliptin does not undergo appreciable metabo-
lism; it produces 6 metabolites, 3 of these active, which 
do not seem to contribute to its pharmacodynamic 
profile.50,53 It is mainly excreted unchanged in the 
urine. A single-dose study was conducted to evaluate 
the pharmacokinetics of 50mg sitagliptin in patients 
with varying degrees of CKD compared to normal 
healthy controls.54 Patients with mild CKD (CrCl 
50-80 mL/min) did not have a clinically meaningful 
increase in the plasma concentration of the drug. 
In patients with moderate (CrCl 30-50mL/min) and 
severe CKD (CrCl <30mL/min), and in those on 
hemodialysis, a 2.3-, 3.8- and 4.5-fold increase in 
the plasma AUC of sitagliptin was observed and the 
terminal t½ values were raised to 19.1, 22.5, and 28.4 
hours, respectively. Sitagliptin was modestly removed 
by hemodialysis. In a 54-week randomized, double-
blind trial which evaluated the safety and efficacy of 
sitagliptin in patients with T2DM and moderate to 
severe CKD and ESRD on dialysis, sitagliptin was 
generally well tolerated and effective.55 The overall 
incidence of drug-related and serious adverse effects 
was similar between groups. In summary, sitagliptin 
dose adjustments are recommended for patients 
with T2DM and moderate to severe renal failure 
(50mg/day and 25mg/day, respectively), as for those 
on dialysis (25mg/day).54,56
Vildagliptin is extensively metabolized into a 
major biologically inactive metabolite and 4 minor 
metabolites.53 The main route of elimination is me-
tabolism, with only approximately 25% of the drug 
excreted by the kidneys.57 Vildagliptin has low po-
tential for drug to drug interactions because it does 
not inhibit or induce CYP enzymes.56 Compared to 
subjects with normal renal function, in patients with 
mild, moderate, and severe CKD, and on hemodialy-
sis, systemic exposure to vildagliptin was increased 
(Cmax 8-66%; AUC 32-134%). However, changes 
in exposure to vildagliptin did not correlate with 
severity of CKD. Exposure to the main metabolite 
increased with increasing severity of CKD (AUC 
1.6- to 6.7-fold), but this effect did not have clinically 
relevant consequences as the metabolite is inactive. 
Elimination t½ of vildagliptin was not affected by 
CKD.58 In a prospective study of vildagliptin (50mg 
qd) in 515 T2DM patients with moderate (GFR ≥30 
to ≤50mL/min/1.73m2) or severe CKD (GFR <30mL/
min/1.73m2), treatment with vildagliptin added to 
ongoing diabetic therapy was well tolerated, with a 
safety profile comparable to placebo.59 A prospective, 
open-label, parallel group, controlled study evaluated 
the efficacy and safety of vildagliptin in 51 Japanese 
diabetic patients undergoing hemodialysis.60 After a 
24-week period, no serious adverse effects such as 
hypoglycemia or liver impairment were observed in any 
patient. Vildagliptin was effective as a treatment for 
diabetic patients undergoing hemodialysis (decreased 
average HbA1c levels from 6.7% baseline to 6.1%, 
and average glycated albumin levels from 24.5% 
baseline to 20.5%, p <0.0001). No dosage adjustment 
is required in patients with mild CKD (CrCl ≥50mL/
min).4 In patients with moderate or severe CKD or 
with ESRD, the recommended dose of vildagliptin is 
50 mg once daily. Since there is limited experience in 
patients on hemodialysis, vildagliptin should be used 
with caution in these patients. 
Saxagliptin is extensively metabolized, primarily 
by cytochrome P450 3A4/5.56 The major metabolite 
(M2) has half the potency of saxagliptin. Saxagliptin 
and M2 are eliminated by hepatic and renal routes.61 
In patients with mild CKD, the AUC of saxagliptin 
and M2 was 1.2- and 1.7- fold higher than in patients 
with normal renal function.62 This increase was not 
considered clinically relevant and no dosage adjust-
ment is recommended. In patients with moderate or 
severe CKD, the AUC and M2 were up to 2.1- and 
4.5- fold higher than in patients with normal renal 
function. A randomized 52-week trial conducted 
in 170 T2DM patients with CrCl <50mL/min or 
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ESRD, which evaluated the efficacy and safety of 
saxagliptin 2.5mg once daily versus placebo, showed 
a low frequency of mainly mild hypoglycemic events 
(28% versus 29%, respectively) and saxagliptin was 
well tolerated.63 It has recently been demonstrated 
that saxagliptin is able to reduce the development 
and progression of microalbuminuria.64 Patients with 
moderate to severe CKD should not receive more 
than 2.5mg/day; in patients with ESRD the drug can 
be taken after hemodialysis.4,62
Alogliptin does not suffer appreciable metabolism 
and around 80% is eliminated unchanged in urine.53 
Metabolism of alogliptin is mediated by cytochrome 
P 450 to active (M-I) and inactive (M-II) metabolites. 
The results of a single dose (50mg) in patients with 
CKD showed an increase in alogliptin exposure in 
comparison with healthy volunteers: approximately 
1.7-, 2.1-, 3.2-, and 3.8- fold, respectively, in patients 
with mild, moderate, severe CKD and in patients on 
dialysis.65 It is advised that patients with moderate 
CKD should receive half of the recommended dose 
and patients with severe CKD or ESRD should receive 
a quarter of the dose.4
Linagliptin does not undergo appreciable me-
tabolism.53 Exposure to its major metabolite, which 
is inactive, was about 18% of the parent compound. 
A study investigating the pharmacokinetic profile of 
14C-linagliptin demonstrated that after oral admin-
istration, 84.7% of the dose was excreted in feces, 
whereas renal excretion accounted for 5.4% of the 
dose.50 Another study conducted in patients with 
and without T2DM with different degrees of CKD 
showed renal excretion <7% in all groups.66 Under 
single-dose conditions, the degree of renal impairment 
did not affect plasma linagliptin concentration time 
profiles. Since renal excretion is a minor elimination 
pathway of linagliptin at therapeutic dose levels, a 
dose adjustment in patients with CKD is not required.4
Dopamine receptor agonist
Bromocriptine was first approved by the FDA 
in 1978 for the treatment of Parkinson’s disease, 
hyperprolactinemia, and acromegaly.67 Bromocrip-
tine has now been reformulated into a quick-release 
formulation for the treatment of T2DM in adults and 
this formulation and indication were approved by 
the FDA in 2009. Although its mechanism of action 
is unknown, bromocriptine mesylate improves post-
prandial glucose without increasing plasma insulin 
concentrations. Bromocriptine mesylate has a high 
bioavailability, between 65% and 95%, and reaches 
peak plasma concentrations in 45 to 60 minutes if 
taken on an empty stomach, later if taken after a 
meal.68 It is 90-96% bound to plasma proteins and is 
extensively metabolized in the gastrointestinal tract 
and liver. The major route of bromocriptine excre-
tion is in the bile with the remaining approximately 
2-6% of an oral dose excreted via the urine. The 
elimination half-life is approximately 6 hours. Studies 
in patients with CKD are limited,69 so it should not 
be used in patients with reduced GFR until more 
evidence is available.
Sodium-glucose co-transporter 2 inhibitors
The SGLTs are a family of membrane proteins 
which transport glucose across the brush-border 
membrane of the proximal renal tubule and across 
the intestinal epithelium.70 SGLT1 and SGLT2 are 
the most studied co-transporters. Over 90% of filtered 
glucose is reabsorbed in the earlier segments of the 
proximal tubule via SGLT2; SGLT1, located in the 
distal segments, absorbs the remainder.71 A novel 
class of oral anti-diabetic drugs, the SGLT2 inhibitors, 
block the reabsorption of filtered glucose, leading to 
glycosuria with consequent glycemic control improve-
ment.72 Dapagliflozin is the first drug in this class 
approved by the EMA. Improvements in glycemic 
parameters have been observed with dapagliflozin 
when administered as monotherapy, as in combination 
therapy, with a 10-mg dapagliflozin once-daily dose 
appearing to show the optimal benefit-risk profile.73 
In studies that evaluated the pharmacokinetics and 
pharmacodynamics of dapagliflozin, it demonstrated 
linear pharmacokinetics over the dose range of 2.5 
to 500 mg and a dose-dependent increase in urinary 
glucose excretion over 24 hours.74 Dapagliflozin was 
rapidly absorbed after oral administration and Cmax 
were observed within 2 h. The mean t½ after the 
last dose ranged from 11.2 to 16.6h. A recent meta-
analysis showed that in patie nts with moderate renal 
impairment, use of dapagliflozin was associated with 
increased incidence of renal-related adverse events.75 
A multicenter trial is ongoing to evaluate the gly-
cemic efficacy, renal safety, pharmacokinetics, and 
pharmacodynamics of dapagliflozin in subjects with 
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T2DM and moderate CKD.76 Although renal func-
tion does not seem to be affected,77 its use in patients 
with moderate to severe CKD (CrCl <60ml/min or 
eGFR <60ml/min) is not recommended. Since the 
elimination depends on kidney function, dapagliflozin 
is less effective if GFR decreases.
G-protein coupled receptor 40 agonists
G-protein coupled receptors are a superfamily of 
membrane proteins activated by a variety of endog-
enous ligands such as hormones, neurotransmitters, 
peptides, proteins, steroids, fatty acids (FAs), and 
other lipids.78 GPR40 is a member of this family, highly 
expressed in pancreatic β cells and in other insulin-
secreting cell lines. FAs act as signaling molecules 
and have glucose-dependent insulinotropic effects 
mediated through activation of GPR40.79 TAK-875 is a 
novel highly selective, orally available GPR40 agonist,80 
and in a study conducted in patients with T2DM it 
showed good tolerability with no dose-limiting side 
effects.81 TAK-875 showed reductions from baseline 
in fasting (2 to -93 mg/dl) and post-OGTT glucose 
(26 to -172 mg/dl), with an apparent dose-dependent 
increase in post-OGTT C-peptide over 14 days. Con-
sistent with preclinical data, TAK-875 apparently acts 
as a glucose-dependent insulinotropic drug with low 
hypoglycemic risk. Currently, there are no data on 
the safety of TAK-875 in patients with CKD.
concLuSIon
Treating T2DM patients with CKD is a great chal-
lenge. The increasing availability of different classes of 
oral glucose-lowering drugs requires physicians to be 
aware of their mechanism of action, pharmacokinetics, 
and safety. In addition, the recommendations on the 
use of the same agent according to the degree of renal 
impairment may differ between countries. While in the 
USA the use of metformin is contraindicated in men 
with serum Cr ≥1.5mg/dL (and in women with serum 
Cr ≥1.4mg/dL), its use is allowed in the UK until GFR 
of 45mL/min/1.73m2, with dose adjustment advised 
for GFR between 30-45 mL/min/1.73m2. Although 
the exact GFR cutoff for metformin use to avoid 
lactic acidosis is controversial, the benefit of its use in 
patients without other risk factors for lactic acidosis 
seems to outweigh its risks. Sulfonylureas are not all 
the same. Glibenclamide should be avoided in patients 
with moderate to severe CKD. Glimepiride may be 
used in patients with CKD stages 3 and 4 with dose 
adjustment (1mg), but its use should be discouraged 
since there are less dangerous alternatives. Although 
glipizide and gliclazide may be used in patients with 
CKD stages 3 to 5 without dose adjustment, caution 
must be exercised due to the risk of hypoglycemia, and 
other classes with a safer profile should be favored. 
Nateglinide and repaglinide can be used in moder-
ate to severe CKD, with dose adjustment advised for 
patients with GFR <30mL/min/1.73m2 (nateglinide 
should be initiated at 60mg and repaglinide at 0.5mg 
dose, both with meals). Since pioglitazone is mainly 
hepatically eliminated, it may be used in patients 
with CKD in stages 3 to 5 without dose adjustment. 
However, caution should be taken with in regard to 
the development of fluid retention and worsening 
of bone disease. Acarbose and miglitol should not 
be used in patients with severe CKD. The DPP-4 
inhibitors may all be used in moderate to severe CKD 
and in dialysis. Of these, linagliptin is the only one 
with insignificant renal elimination and it does not 
require dose adjustment. Fifty percent dose reduc-
tion is recommended for sitagliptin (50mg daily) and 
alogliptin (12.5mg) in patients with CrCl 30-50 mL/
min and a 75% dose reduction (respectively 25mg and 
6.25mg daily) for CrCl <30mL/min. Fifty percent dose 
reduction is also advised for vildagliptin (50mg daily) 
and saxagliptin (2.5mg daily) in patients with CrCl 
<50mL/min. Bromocriptine mesylate is a new drug 
approved for the treatment of T2DM but evidence 
in patients with CKD is scarce, so its use should be 
discouraged. Emerging classes of anti-diabetic drugs 
are in development, such as the SGLT inhibitors and 
the GPR40 agonists, but there are still no data on their 
potential use in patients with impaired renal function.
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